131 related articles for article (PubMed ID: 7772678)
1. Angiotensin-converting enzyme inhibition reduces diabetes-induced vascular hypertrophy: morphometric studies.
Vranes D; Cooper ME; Dilley RJ
J Vasc Res; 1995; 32(3):183-9. PubMed ID: 7772678
[TBL] [Abstract][Full Text] [Related]
2. Diabetes-associated mesenteric vascular hypertrophy is attenuated by angiotensin-converting enzyme inhibition.
Cooper ME; Rumble J; Komers R; Du HC; Jandeleit K; Chou ST
Diabetes; 1994 Oct; 43(10):1221-8. PubMed ID: 7926292
[TBL] [Abstract][Full Text] [Related]
3. Attenuation of diabetes-associated mesenteric vascular hypertrophy with perindopril: morphological and molecular biological studies.
Cooper ME; Cao Z; Rumble JR; Jandeleit K; Allen TJ; Gilbert RE
Metabolism; 1998 Dec; 47(12 Suppl 1):24-7. PubMed ID: 9867067
[TBL] [Abstract][Full Text] [Related]
4. Kinins or nitric oxide, or both, are involved in the antitrophic effects of angiotensin converting enzyme inhibitors on diabetes-associated mesenteric vascular hypertrophy in the rat.
Rumble JR; Komers R; Cooper ME
J Hypertens; 1996 May; 14(5):601-7. PubMed ID: 8762203
[TBL] [Abstract][Full Text] [Related]
5. Vascular changes in the diabetic kidney: effects of ACE inhibition.
Vranes D; Dilley RJ; Cooper ME
J Diabetes Complications; 1995; 9(4):296-300. PubMed ID: 8573751
[TBL] [Abstract][Full Text] [Related]
6. Role of angiotensin II in early cardiovascular growth and vascular amplifier development in spontaneously hypertensive rats.
Black MJ; Kanellakis P; Bobik A
J Hypertens; 1997 Sep; 15(9):945-54. PubMed ID: 9321741
[TBL] [Abstract][Full Text] [Related]
7. Cellular mechanisms of diabetic vascular hypertrophy.
Vranes D; Cooper ME; Dilley RJ
Microvasc Res; 1999 Jan; 57(1):8-18. PubMed ID: 9882558
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin converting enzyme inhibition and calcium antagonism attenuate streptozotocin-diabetes-associated mesenteric vascular hypertrophy independently of their hypotensive action.
Cao Z; Hulthén UL; Allen TJ; Cooper ME
J Hypertens; 1998 Jun; 16(6):793-9. PubMed ID: 9663919
[TBL] [Abstract][Full Text] [Related]
9. Long-term effects of the endothelin(A) receptor antagonist LU 135252 and the angiotensin-converting enzyme inhibitor trandolapril on diabetic angiopathy and nephropathy in a chronic type I diabetes mellitus rat model.
Dhein S; Hochreuther S; Aus Dem Spring C; Bollig K; Hufnagel C; Raschack M
J Pharmacol Exp Ther; 2000 May; 293(2):351-9. PubMed ID: 10773002
[TBL] [Abstract][Full Text] [Related]
10. Protective effect of the angiotensin-converting enzyme inhibitor perindopril on diabetic glomerulopathy in streptozotocin-induced diabetic rats.
Yan L; Yang R; Cheng H; Fu Z; Zhong G; Yan T
Chin Med J (Engl); 1998 Apr; 111(4):306-8. PubMed ID: 10374392
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular hypertrophy in diabetic spontaneously hypertensive rats: optimizing blockade of the renin-angiotensin system.
Lassila M; Davis BJ; Allen TJ; Burrell LM; Cooper ME; Cao Z
Clin Sci (Lond); 2003 Apr; 104(4):341-7. PubMed ID: 12653675
[TBL] [Abstract][Full Text] [Related]
12. The effects of perindopril on vascular smooth muscle polyploidy in stroke-prone spontaneously hypertensive rats.
Devlin AM; Gordon JF; Davidson AO; Clark JS; Hamilton CA; Morton JJ; Campbell AM; Reid JL; Dominiczak AF
J Hypertens; 1995 Feb; 13(2):211-8. PubMed ID: 7615951
[TBL] [Abstract][Full Text] [Related]
13. Heparin inhibits mesenteric vascular hypertrophy in angiotensin II-infusion hypertension in rats.
Dilley RJ; Nataatmadja MI
Cardiovasc Res; 1998 Apr; 38(1):247-55. PubMed ID: 9683928
[TBL] [Abstract][Full Text] [Related]
14. Antihypertensive therapy and diabetic microvascular disease.
Cooper ME
Clin Exp Hypertens; 1997; 19(5-6):769-78. PubMed ID: 9247754
[TBL] [Abstract][Full Text] [Related]
15. Vascular effects of perindopril: from experimental to clinical investigation.
Scalbert E; Levy B; Desche P; Devissaguet M; Safar ME
J Cardiovasc Pharmacol; 1991; 18 Suppl 7():S25-32. PubMed ID: 1725197
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin converting enzyme inhibition reduces the expression of transforming growth factor-beta1 and type IV collagen in diabetic vasculopathy.
Rumble JR; Gilbert RE; Cox A; Wu L; Cooper ME
J Hypertens; 1998 Nov; 16(11):1603-9. PubMed ID: 9856360
[TBL] [Abstract][Full Text] [Related]
17. The angiotensin-converting enzyme inhibitor, perindopril, prevents cardiac hypertrophy in low-renin hypertensive rats.
Nakamura F; Nagano M; Higaki J; Higashimori K; Morishita R; Mikami H; Ogihara T
Clin Exp Pharmacol Physiol; 1993 Mar; 20(3):135-40. PubMed ID: 8467569
[TBL] [Abstract][Full Text] [Related]
18. Effects of angiotensin-converting enzyme inhibition on angiotensin and bradykinin peptides in rats with myocardial infarction.
Duncan AM; Burrell LM; Kladis A; Campbell DJ
J Cardiovasc Pharmacol; 1996 Dec; 28(6):746-54. PubMed ID: 8961071
[TBL] [Abstract][Full Text] [Related]
19. Diabetes-induced vascular hypertrophy is accompanied by activation of Na(+)-H(+) exchange and prevented by Na(+)-H(+) exchange inhibition.
Jandeleit-Dahm K; Hannan KM; Farrelly CA; Allen TJ; Rumble JR; Gilbert RE; Cooper ME; Little PJ
Circ Res; 2000 Dec; 87(12):1133-40. PubMed ID: 11110770
[TBL] [Abstract][Full Text] [Related]
20. Effect of chronic ANG I-converting enzyme inhibition on aging processes. II. Large arteries.
Michel JB; Heudes D; Michel O; Poitevin P; Philippe M; Scalbert E; Corman B; Levy BI
Am J Physiol; 1994 Jul; 267(1 Pt 2):R124-35. PubMed ID: 8048614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
